Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed Glioblastoma

This is the authors' abstract. We don't add key points for this paper.

The addition of bevacizumab to radiotherapy-temozolomide did not improve survival in patients with glioblastoma. Improved progression-free survival and maintenance of baseline quality of life and performance status were observed with bevacizumab; however, the rate of adverse events was higher with bevacizumab than with placebo. (Funded by F. Hoffmann-La Roche; ClinicalTrials.gov number, NCT00943826.).